Loading...
Dupilumab and COVID‐19: What should we expect?
Coronavirus disease 2019 (COVID‐19) is a pandemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) with high morbidity and mortality. There are very limited data on the interference of immunomodulating drugs on the risk of infection and on the course of the disease. In...
Saved in:
| Published in: | Dermatol Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley & Sons, Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7267436/ https://ncbi.nlm.nih.gov/pubmed/32362061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.13502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|